Related Experiment Video
Updated: Jul 3, 2026
04:20
Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study.
Ozhan Ozdogan1, Turkan Ertay, Gulhan Arslan
1Department of Nuclear Medicine, Dokuz Eylul University School of Medicine, Inciralti, Izmir 35340, Turkey. ozhan.ozdogan@deu.edu.tr
Annals of Nuclear Medicine
|July 5, 2008
Summary
Cisplatin chemotherapy does not affect Technetium-99m methylenediphosphonic acid (Tc-99m MDP) bone uptake in normal bone. This study found no significant difference in bone scan uptake after cisplatin administration in rats.
Area of Science:
- Nuclear medicine
- Oncology
- Pharmacology
Background:
- Bone scintigraphy is the standard initial imaging for skeletal metastases.
- Cisplatin, a chemotherapy agent, interacts with phosphate compounds like MDP.
- This interaction suggests cisplatin might reduce Tc-99m MDP bone uptake.
Purpose of the Study:
- To investigate if cisplatin chemotherapy affects Tc-99m MDP bone uptake.
- To determine the duration of any potential effect of cisplatin on bone uptake.
Main Methods:
- Thirty male Wistar rats were divided into placebo and cisplatin groups.
- Bone scintigraphies were performed pre- and post-cisplatin treatment at various time points (10 min to 72 h).
- Quantitative analysis of bone uptake ratios and plasma cisplatin levels were measured.
Main Results:
- No statistically significant differences in bone uptake values were observed between groups.
- Injected MDP doses and injection/examination time delays were consistent across all groups.
- Cisplatin plasma levels were significantly elevated in treated rats, confirming drug administration.
Conclusions:
- Cisplatin chemotherapy does not appear to alter Tc-99m MDP uptake in normal bone.
- The study did not find evidence of cisplatin impacting the standard bone scan imaging agent.
